CAREDX INC (CDNA) Stock Fundamental Analysis
USA - NASDAQ:CDNA - US14167L1035 - Common Stock
15 USD
+0.53 (+3.66%)
15 USD
0 (0%)
Taking everything into account, CDNA scores 5 out of 10 in our fundamental rating. CDNA was compared to 534 industry peers in the Biotechnology industry. Both the profitability and the financial health of CDNA get a neutral evaluation. Nothing too spectacular is happening here. CDNA is growing strongly while it is still valued neutral. This is a good combination!
1. Profitability
1.1 Basic Checks
In the past year CDNA was profitable.
In the past year CDNA had a positive cash flow from operations.
CDNA had negative earnings in 4 of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: CDNA reported negative operating cash flow in multiple years.
1.2 Ratios
Looking at the Return On Assets, with a value of 11.63%, CDNA belongs to the top of the industry, outperforming 94.38% of the companies in the same industry.
The Return On Equity of CDNA (15.79%) is better than 94.94% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.63% | ||
| ROE | 15.79% | ||
| ROIC | N/A |
ROA(3y)-14.72%
ROA(5y)-10.93%
ROE(3y)-25.57%
ROE(5y)-18.01%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
CDNA has a Profit Margin of 15.16%. This is amongst the best in the industry. CDNA outperforms 93.26% of its industry peers.
CDNA's Gross Margin of 66.90% is amongst the best of the industry. CDNA outperforms 80.52% of its industry peers.
In the last couple of years the Gross Margin of CDNA has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 15.16% | ||
| GM | 66.9% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.01%
GM growth 5Y0.9%
2. Health
2.1 Basic Checks
CDNA does not have a ROIC to compare to the WACC, probably because it is not profitable.
CDNA has more shares outstanding than it did 1 year ago.
The number of shares outstanding for CDNA has been increased compared to 5 years ago.
There is no outstanding debt for CDNA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
CDNA has an Altman-Z score of 2.74. This is not the best score and indicates that CDNA is in the grey zone with still only limited risk for bankruptcy at the moment.
CDNA has a better Altman-Z score (2.74) than 68.16% of its industry peers.
There is no outstanding debt for CDNA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 2.74 |
ROIC/WACCN/A
WACC8.75%
2.3 Liquidity
CDNA has a Current Ratio of 3.30. This indicates that CDNA is financially healthy and has no problem in meeting its short term obligations.
CDNA has a worse Current ratio (3.30) than 60.86% of its industry peers.
CDNA has a Quick Ratio of 3.00. This indicates that CDNA is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 3.00, CDNA is not doing good in the industry: 61.42% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.3 | ||
| Quick Ratio | 3 |
3. Growth
3.1 Past
CDNA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 492.31%, which is quite impressive.
Measured over the past years, CDNA shows a very strong growth in Earnings Per Share. The EPS has been growing by 37.47% on average per year.
The Revenue has grown by 14.72% in the past year. This is quite good.
Measured over the past years, CDNA shows a very strong growth in Revenue. The Revenue has been growing by 21.30% on average per year.
EPS 1Y (TTM)492.31%
EPS 3Y23.03%
EPS 5Y37.47%
EPS Q2Q%-60%
Revenue 1Y (TTM)14.72%
Revenue growth 3Y4.04%
Revenue growth 5Y21.3%
Sales Q2Q%-6.06%
3.2 Future
The Earnings Per Share is expected to grow by 37.54% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 11.66% on average over the next years. This is quite good.
EPS Next Y1.06%
EPS Next 2Y22.93%
EPS Next 3Y37.54%
EPS Next 5YN/A
Revenue Next Year11.33%
Revenue Next 2Y11.62%
Revenue Next 3Y11.66%
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 29.41 indicates a quite expensive valuation of CDNA.
CDNA's Price/Earnings ratio is rather cheap when compared to the industry. CDNA is cheaper than 94.01% of the companies in the same industry.
CDNA is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 26.10, which is the current average of the S&P500 Index.
The Price/Forward Earnings ratio is 18.38, which indicates a rather expensive current valuation of CDNA.
Based on the Price/Forward Earnings ratio, CDNA is valued cheaply inside the industry as 94.01% of the companies are valued more expensively.
When comparing the Price/Forward Earnings ratio of CDNA to the average of the S&P500 Index (22.52), we can say CDNA is valued inline with the index average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 29.41 | ||
| Fwd PE | 18.38 |
4.2 Price Multiples
CDNA's Price/Free Cash Flow ratio is rather cheap when compared to the industry. CDNA is cheaper than 92.13% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 67.22 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates CDNA does not grow enough to justify the current Price/Earnings ratio.
A more expensive valuation may be justified as CDNA's earnings are expected to grow with 37.54% in the coming years.
PEG (NY)27.86
PEG (5Y)0.78
EPS Next 2Y22.93%
EPS Next 3Y37.54%
5. Dividend
5.1 Amount
No dividends for CDNA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
15
+0.53 (+3.66%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners102.13%
Inst Owner Change-0.54%
Ins Owners2.37%
Ins Owner Change1.2%
Market Cap798.45M
Revenue(TTM)340.83M
Net Income(TTM)51.68M
Analysts80
Price Target22.95 (53%)
Short Float %11.79%
Short Ratio4.56
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)8.98%
Min EPS beat(2)-18.08%
Max EPS beat(2)36.04%
EPS beat(4)3
Avg EPS beat(4)331.94%
Min EPS beat(4)-18.08%
Max EPS beat(4)1272.55%
EPS beat(8)7
Avg EPS beat(8)222.06%
EPS beat(12)11
Avg EPS beat(12)158.17%
EPS beat(16)12
Avg EPS beat(16)125.68%
Revenue beat(2)0
Avg Revenue beat(2)-3.92%
Min Revenue beat(2)-6.22%
Max Revenue beat(2)-1.61%
Revenue beat(4)2
Avg Revenue beat(4)-1.5%
Min Revenue beat(4)-6.22%
Max Revenue beat(4)0.91%
Revenue beat(8)6
Avg Revenue beat(8)8.02%
Revenue beat(12)7
Avg Revenue beat(12)5.22%
Revenue beat(16)8
Avg Revenue beat(16)3.59%
PT rev (1m)0%
PT rev (3m)-23.91%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-4.71%
EPS NY rev (1m)0%
EPS NY rev (3m)-10.8%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.19%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.52%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 29.41 | ||
| Fwd PE | 18.38 | ||
| P/S | 2.34 | ||
| P/FCF | 67.22 | ||
| P/OCF | 45.05 | ||
| P/B | 2.44 | ||
| P/tB | 3.18 | ||
| EV/EBITDA | N/A |
EPS(TTM)0.51
EY3.4%
EPS(NY)0.82
Fwd EY5.44%
FCF(TTM)0.22
FCFY1.49%
OCF(TTM)0.33
OCFY2.22%
SpS6.4
BVpS6.15
TBVpS4.72
PEG (NY)27.86
PEG (5Y)0.78
Graham Number8.4
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.63% | ||
| ROE | 15.79% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | 15.16% | ||
| GM | 66.9% | ||
| FCFM | 3.49% |
ROA(3y)-14.72%
ROA(5y)-10.93%
ROE(3y)-25.57%
ROE(5y)-18.01%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.01%
GM growth 5Y0.9%
F-Score7
Asset Turnover0.77
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 41.29% | ||
| Cap/Sales | 1.71% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | 22.98% | ||
| Current Ratio | 3.3 | ||
| Quick Ratio | 3 | ||
| Altman-Z | 2.74 |
F-Score7
WACC8.75%
ROIC/WACCN/A
Cap/Depr(3y)106.55%
Cap/Depr(5y)139.53%
Cap/Sales(3y)4.27%
Cap/Sales(5y)5%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)492.31%
EPS 3Y23.03%
EPS 5Y37.47%
EPS Q2Q%-60%
EPS Next Y1.06%
EPS Next 2Y22.93%
EPS Next 3Y37.54%
EPS Next 5YN/A
Revenue 1Y (TTM)14.72%
Revenue growth 3Y4.04%
Revenue growth 5Y21.3%
Sales Q2Q%-6.06%
Revenue Next Year11.33%
Revenue Next 2Y11.62%
Revenue Next 3Y11.66%
Revenue Next 5YN/A
EBIT growth 1Y35.56%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year115.46%
EBIT Next 3Y72.56%
EBIT Next 5YN/A
FCF growth 1Y185.03%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y6229.29%
OCF growth 3YN/A
OCF growth 5YN/A
CAREDX INC / CDNA FAQ
What is the ChartMill fundamental rating of CAREDX INC (CDNA) stock?
ChartMill assigns a fundamental rating of 5 / 10 to CDNA.
Can you provide the valuation status for CAREDX INC?
ChartMill assigns a valuation rating of 5 / 10 to CAREDX INC (CDNA). This can be considered as Fairly Valued.
What is the profitability of CDNA stock?
CAREDX INC (CDNA) has a profitability rating of 4 / 10.
What is the valuation of CAREDX INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for CAREDX INC (CDNA) is 29.41 and the Price/Book (PB) ratio is 2.44.